Clinical Trial Update: Influence of Intensive Lipid-lowering on FFRCT (The FLOW-PROMOTE Study) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update investigating the impact of intensive lipid-lowering therapy on fractional flow reserve by CT (FFRCT) in coronary artery disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Snippet

Sponsor: Bjarne Linde Noergaard | Conditions: Coronary Artery Disease | Phase 3 | Status: UNKNOWN